New Pabron Ace Granule Launched
Contains Three Set of Special Ingredients

Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) put on sale a new version of its comprehensive cold medication Pabron Ace Granule on August 19.

The new Pabron Ace Granule’s three set of special ingredients—bromohexine hydrochloride, ibuprofen, and lysozyme chloride—target four hard-to-bear cold symptoms: sore throat, cough, fever, and runny or stuffy nose. The new product is a granular version of the Pabron Ace tablets put on sale in January.

Since Taisho Pharmaceutical’s launch of Pabron cough medicine in 1927, the company has continually expanded the Pabron line, developing new products and reformulating existing products to meet consumer demand for comprehensive cold relief. Consumers can be divided into those who purchase cold medication regularly and those who buy it as needed. While Taisho Pharmaceutical’s Pabron S Gold is positioned as basic stand-by, a cold medication for every member of the family, Pabron Ace is positioned as an adult cold remedy. Together, these products are the pillars of a strategy that provides consumers with comprehensive relief from the suffering caused by colds.